Alnylam Pharmaceuticals stock (US02005N1000): Backs TTR revenue outlook amid AMVUTTRA growth

Alnylam Pharmaceuticals reaffirmed its full-year TTR revenue guidance of $4.4-4.7 billion, attributing Q1 slowdown to expected factors while highlighting AMVUTTRA access and prescriber expansion as key drivers for acceleration.

Alnylam Pharmaceuticals recently reaffirmed its full-year TTR revenue guidance of $4.4 billion to $4.7 billion, with Chief Financial Officer Jeff Poulton noting that the first-quarter sequential slowdown was anticipated. The company reported $910 million in TTR revenue for Q1 2026, reflecting over 150% year-over-year growth, primarily driven by AMVUTTRA, according to MarketBeat as of 05/13/2026. Management expects sequential quarterly growth to average around $150 million for the remainder of the year to hit guidance midpoint, fueled by improved access, international launches, and prescriber base expansion.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Alnylam Pharmaceuticals, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Global, with strong US presence
• Key revenue drivers: RNAi therapeutics, TTR franchise
• Home exchange/listing venue: Nasdaq (ALNY)
• Trading currency: USD

Alnylam Pharmaceuticals: core business model

Alnylam Pharmaceuticals focuses on developing and commercializing RNA interference (RNAi) therapeutics, a platform that silences disease-causing genes. The company targets rare and prevalent diseases across therapeutic areas including ATTR amyloidosis, hyperoxaluria, and hemophilia. Its lead products like AMVUTTRA (vutrisiran) address transthyretin-mediated (TTR) amyloidosis, a key revenue pillar for US investors tracking biotech innovation in genetic medicines.

Alnylam operates primarily in the US market via Nasdaq listing, with global reach through partnerships and launches. The business model emphasizes proprietary RNAi technology licensed from collaborators, enabling subcutaneous and intravenous delivery systems that differentiate it in the competitive biotech landscape.

Main revenue and product drivers for Alnylam Pharmaceuticals

AMVUTTRA remains the cornerstone of Alnylam's TTR franchise, contributing the vast majority of the $910 million Q1 2026 TTR revenue reported on May 13, 2026. Management highlighted broad formulary placement, with over 90% patient access via infusion-clinic networks, positioning it for US market dominance in ATTR treatment, per MarketBeat as of 05/13/2026.

International expansion and prescriber growth are set to drive sequential acceleration, supporting the reaffirmed $4.4-4.7 billion full-year TTR guidance published for 2026. Additional pipeline assets in clinical development bolster long-term revenue potential for this Nasdaq-listed biotech.

Industry trends and competitive position

The RNAi therapeutics sector is expanding amid advances in gene silencing technologies, with Alnylam leading in TTR amyloidosis treatments. Competitors like Incyte trail on multiple factors, while Alnylam's AMVUTTRA benefits from established access infrastructure relevant to US healthcare providers and payers.

Why Alnylam Pharmaceuticals matters for US investors

As a Nasdaq-listed biotech headquartered in the US, Alnylam offers exposure to innovative genetic medicines with significant US revenue from AMVUTTRA sales. Its TTR franchise growth aligns with rising demand for ATTR therapies in the American market, where aging demographics drive amyloidosis prevalence.

Conclusion

Alnylam Pharmaceuticals demonstrated confidence in its TTR revenue trajectory by backing full-year guidance despite Q1 dynamics, with AMVUTTRA positioned as the primary growth engine through enhanced access and expansion. US investors monitor these developments amid biotech sector volatility. Ongoing pipeline progress and market penetration will shape future performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.